TR4NSFORM
TR4NSFORM

Signals of transformation

Evidence that moves medicine forward.

Breakthroughs. Better outcomes. New biological possibilities.

A living intelligence feed following meaningful movement across psychedelic medicine, cannabinoid science, neuroplasticity, longevity, and regenerative biomedicine.

  • Primary-source linked
  • Evidence-stage visible
  • Date anchored

Medicine is moving.

Selected developments with a direct route to the primary paper or trial record.

Four curated Signals are available.

Featured signal Human study · exploratory

First-time psilocybin study maps brain change and improved well-being at one month

A placebo-controlled multimodal study of 28 psychedelic-naive participants detected anatomical and functional changes after 25 mg psilocybin. Acute brain entropy predicted later psychological insight and well-being.

Open primary paper in a new tab

Clinical result Phase 3

Full-spectrum cannabis extract meets its primary endpoint in chronic low-back pain

In an 820-person randomized trial, the chemically defined extract produced a statistically greater reduction in pain than placebo and improved neuropathic symptoms, sleep quality, and physical function.

Open primary paper in a new tab

Mechanism Preclinical

Psilocybin increases dendritic spine density in key frontal-cortex neurons

Cell-type-specific imaging linked psilocybin-induced structural plasticity to 5-HT2A receptors and identified the pyramidal neurons required for its long-term stress-related behavioural effects.

Open primary paper in a new tab

Trial watch Registered

Psilocybin is being tested for synaptic-density change in mild cognitive impairment

A placebo-controlled study is investigating whether psilocybin changes synaptic vesicle density—and whether any change is associated with cognitive improvement—in amnestic mild cognitive impairment.

Open trial record in a new tab

See what changed—and where the evidence sits.

Human outcomes

What changed for people?

Clinical and observational Signals foreground participants, endpoints, study design, and reported outcome movement.

Biological mechanism

What is becoming measurable?

Mechanistic Signals track cellular, neural, metabolic, and regenerative findings while keeping preclinical evidence clearly identified.

Trial horizon

What is being tested next?

Registered-trial Signals follows active questions, study status, and the primary registry record before results exist.

Find what is working. Track what becomes possible.

Built for forward motion

Signals prioritises discoveries, outcome movement, new mechanisms, clinical progress, and the research changing how health can be approached. Deeper intelligence connects these developments to the gateway’s protocol library.